


## Intraductal cisplatin treatment in a *BRCA*-associated breast cancer mouse model attenuates tumor development but leads to systemic tumors in aged female mice


### Supplementary Material



Supplementary Figure 1: Tumor latency and incidence in control WAPCre;Brca1F/F;Trp53F/F.

(A) Tumor latency in control mice (n=24) in days after birth.

(B) Breast tumor incidence in control mice depicted for the separate mammary glands.



**Supplementary Figure 2: PCR results for floxed regions of Brca1 and Trp53.** PCR results from from tumor DNA for  $\Delta$ Trp53 (upper row) and  $\Delta$ Brca1 (lower row) of control mice or mice treated with ID cisplatin. In the first two lanes negative and positive control are loaded, respectively.

**For Supplementray Tables see in Supplementary Files**